Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Medscape Medical News, March 19, 2024 SGO 2024 QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer Adding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in ...

A life-extending drug for advanced cervical cancer will be made available to NHS patients in England, like it is in Scotland, new recommendations say. Pembrolizumab can mean extra months of life ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

A new report from leading contract research organisation Novotech has shed light on the current state of play in the global ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

The NCCN 2024 guidelines include recommendations such as chemoradiation and pembrolizumab-based therapies for PD-L1-positive tumors. Treatment options for recurrent or metastatic cervical cancer ...